Combining therapies to improve treatment for colorectal cancer with KRASG12C mutations
Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers
This study is looking at new ways to treat advanced colorectal cancer with a specific KRASG12C mutation by testing a combination of two targeted therapies to see if they can work better together and help patients feel better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10666698 on NIH RePORTER |
What this research studies
This research focuses on developing new treatment strategies for patients with advanced colorectal cancer that has specific KRASG12C mutations. The approach involves testing a combination of two targeted therapies: one that inhibits KRASG12C and another that targets EGFR and PI3K pathways, which are known to contribute to treatment resistance. By using mouse models derived from patient tumors, the researchers aim to evaluate the effectiveness of this combination therapy in overcoming resistance and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced colorectal cancer harboring KRASG12C mutations.
Not a fit: Patients with colorectal cancer that does not have KRASG12C mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with KRASG12C mutant colorectal cancer, potentially improving survival rates.
How similar studies have performed: While there has been progress in targeting KRAS mutations, this specific combination approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Leopold, Judith S — University of Michigan at Ann Arbor
- Study coordinator: Leopold, Judith S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.